# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Asthika Goonewardene maintains IGM Biosciences (NASDAQ:IGMS) with a Buy and lowers the price targe...
Wedbush analyst Robert Driscoll maintains IGM Biosciences (NASDAQ:IGMS) with a Outperform and raises the price target from $...
RBC Capital analyst Brian Abrahams reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.
JP Morgan analyst Eric Joseph maintains IGM Biosciences (NASDAQ:IGMS) with a Neutral and raises the price target from $11 to...
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-...